Target Name: MUC16
NCBI ID: G94025
Review Report on MUC16 Target / Biomarker Content of Review Report on MUC16 Target / Biomarker
MUC16
Other Name(s): Ovarian cancer-related tumor marker CA125 | MUC16_HUMAN | sMUC16_(HUMAN) | CA125 ovarian cancer antigen | Ovarian carcinoma antigen CA125 | cancer antigen 125 | Mucin-16 | ovarian cancer-related tumor marker CA125 | CA-125 | CA125 | mucin-16-like | Mucin 16, cell surface associated | mucin 16, cell surface associated | ovarian carcinoma antigen CA125 | MUC-16 | soluble mucin-16 | Cancer Antigen 125

Targeting MUC16 in Ovarian Cancer

Ovarian cancer is a serious and life-threatening disease, affecting thousands of women worldwide. Despite advances in treatment, the survival rate for ovarian cancer remains high, with a five-year survival rate of only around 40%. Therefore, there is a strong need for new and effective treatments.

One potential drug target for ovarian cancer is MUC16 (Mucin 16), a protein that is overexpressed in ovarian cancer. MUC16 is a transmembrane glycoprotein that is involved in many cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cell growth and apoptosis.

Targeting MUC16 in ovarian cancer

MUC16 has been identified as a potential drug target for ovarian cancer because it is overexpressed in this disease. Studies have shown that MUC16 is overexpressed in ovarian cancer tissues and that targeting this protein may be an effective way to treat this disease.

One way to target MUC16 in ovarian cancer is through inhibition of its signaling pathways. The ALC/TAL1 signaling pathway is a key signaling pathway that is involved in many cellular processes, including cell adhesion, migration, and invasion. MUC16 is a component of the ALC/TAL1 signaling pathway, and it has been shown to be involved in the regulation of cell growth and apoptosis.

Inhibition of MUC16 signaling has been shown to be an effective way to treat ovarian cancer. For example, studies have shown that inhibiting the ALC/TAL1 signaling pathway using drugs such as inhibitors of the protein inhibitor of MUC16 (IPI) has been shown to be effective in treating ovarian cancer. IPI is a protein that is highly expressed in ovarian cancer tissues and has been shown to be involved in the regulation of cell growth and apoptosis.

Another way to target MUC16 in ovarian cancer is through inhibition of its role in cell adhesion. MUC16 is involved in cell adhesion and has been shown to be involved in the regulation of cell migration. Inhibition of MUC16 has been shown to be an effective way to treat ovarian cancer by reducing the ability of cancer cells to migrate and adhere to other tissues.

In conclusion, MUC16 is a protein that is overexpressed in ovarian cancer and has been shown to be involved in the regulation of many cellular processes. Inhibition of MUC16 signaling has been shown to be an effective way to treat ovarian cancer. Further research is needed to understand the full role of MUC16 in ovarian cancer and to develop new and effective treatments.

Protein Name: Mucin 16, Cell Surface Associated

Functions: Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces

The "MUC16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MUC16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MUC17 | MUC19 | MUC2 | MUC20 | MUC20P1 | MUC21 | MUC22 | MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6